18F-fluoromisonidazole

also known as 18F-FMISO · 18-F-MISO · FMISO

Investigated by: National Cancer Institute (NCI) · National Institutes of Health (NIH) · University of Alabama at Birmingham · Abramson Cancer Center at Penn Medicine · Bernardino Clavo, MD, PhD · Cyclopharma
+21 more
· Fundación DISA, Canary Islands, Spain · Grupo de Investigación Clínica en Oncología Radioterapia · H. Lee Moffitt Cancer Center and Research Institute · IASON Gmbh, Feldkirchner strasse 4, 8054 Graz-Seiesberg AUSTRIA · Institut Cancerologie de l'Ouest · Instituto Canario de Investigación del Cáncer · Instituto Tecnologico Servicios Sanitarios, in MD Anderson Cancer Center, Madrid · Instituto de Salud Carlos III · M.D. Anderson Cancer Center · Memorial Sloan Kettering Cancer Center · NRG Oncology · National Institutes of Health Clinical Center (CC) · OHSU Knight Cancer Institute · Oregon Health and Science University · Poitiers University Hospital · RSbiomed · Stanford University · University of Arkansas · University of Pennsylvania · Vanderbilt-Ingram Cancer Center · Weill Cornell University

Trials 15 · a red edge is where a trial was stopped

today NCT04861077 · Ph 0 NCT05996432 · Ph 0 NCT04332588 · Ph 1 NCT03649880 · Ph 2 NCT03730077 · Ph 1 NCT03573986 · Ph 1 NCT02695628 · Ph 2 NCT02471313 · Ph 2 NCT02061007 · Ph 2 NCT02016872 · not/applicable NCT01967927 · Ph 0 NCT01868906 · Ph 2 NCT01898065 · Ph 2 NCT01507428 · Ph 2 NCT00038038 · not/applicable

19931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 03 trials
Phase 0	NCT04861077	Jun 2026 → Aug 2028 expected	triple-negative breast carcinoma	University of Alabama at Birmingham	Recruiting	No outcome recorded
Phase 0	NCT05996432	May 2023 → Nov 2026 expected	head and neck squamous cell carcinoma, metastatic malignant neoplasm in the brain	Vanderbilt-Ingram Cancer Center	Recruiting	No outcome recorded
Phase 0	NCT01967927	Dec 2013 → Aug 2021	head and neck squamous cell carcinoma	University of Arkansas	Withdrawn	No outcome recorded
Phase 13 trials
Phase 1	NCT04332588	Mar 2022 → Aug 2027 expected	HER2 positive breast carcinoma	University of Alabama at Birmingham	Recruiting	No outcome recorded
Phase 1	NCT03730077	Feb 2019 → Feb 2021	soft tissue sarcoma	University of Pennsylvania	Terminated	No outcome recorded
Phase 1	NCT03573986	Apr 2018 → Jan 2020	glioblastoma	Abramson Cancer Center at Penn Medicine	Terminated	No outcome recorded
Phase 27 trials
Phase 2	NCT03649880	Jun 2019 → Jan 2029 expected	brain cancer	OHSU Knight Cancer Institute	Recruiting	No outcome recorded
Phase 2	NCT02695628	Sep 2016 → Apr 2018	cirrhosis of liver, hepatocellular carcinoma	Stanford University	Completed	No outcome recorded
Phase 2	NCT02471313	Jun 2015 → Mar 2018	hepatocellular carcinoma	National Institutes of Health Clinical Center (CC)	Completed	No outcome recorded
Phase 2	NCT02061007	Oct 2014 → Feb 2016	melanoma, skin cancer	H. Lee Moffitt Cancer Center and Research Institute	Withdrawn	No outcome recorded
Phase 2	NCT01868906	Jun 2013 → Sep 2017	malignant glioma	Bernardino Clavo, MD, PhD	Terminated	No outcome recorded
Phase 2	NCT01898065	Jun 2012 → Nov 2014	prostate adenocarcinoma	Institut Cancerologie de l'Ouest	Completed	No outcome recorded
Phase 2	NCT01507428	Feb 2012 → Aug 2020	non-small cell lung carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase not applicable2 trials
—	NCT02016872	Dec 2013 → Jul 2024	non-small cell lung carcinoma	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
—	NCT00038038	Jan 1994 → Jun 2003	head and neck neoplasm, metastatic neoplasm, squamous cell carcinoma	M.D. Anderson Cancer Center	Withdrawn	No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 16 sources stand behind the page.

Field	Value	Cited text
Known as	18F-fluoromisonidazole	“18F-fluoromisonidazole (FMISO) positron emission tomography (PET) is a non-invasive, quantitative imaging technique used to evaluate the presence and spatial distribution of...” PMID 27822900 ↗ Nov 2016 7 NCT03649880 ↗ NCT02695628 ↗ NCT02061007 ↗ NCT01507428 ↗ NCT05996432 ↗ NCT03573986 ↗ NCT00038038 ↗
Known as	18-F-MISO	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01898065 ↗ 1 NCT01967927 ↗
Known as	18F-FMISO	“experimental drug, 18F-fluoromisonidazole (18F-FMISO), visualized with PET scanning.” NCT00038038 ↗ 6 NCT01868906 ↗ NCT02016872 ↗ NCT04861077 ↗ NCT03730077 ↗ NCT04332588 ↗ NCT02471313 ↗
Known as	FMISO	“18F-fluoromisonidazole (FMISO) positron emission tomography (PET) is a non-invasive, quantitative imaging technique used to evaluate the presence and spatial distribution of...” PMID 27822900 ↗ Nov 2016 1 “Fludeoxyglucose (18F) fluoromisonidazole (FMISO), in patients diagnosed with triple negative breast cancer” NCT04861077 ↗
Modality	Diagnostic / imaging agent	“using 18F-fluoromisonidazole as an imaging agent” NCT00038038 ↗
Route	Intravenous	“IV line placed for radiotracer injection” NCT02016872 ↗